Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057447
Status:
TERMINATED
Last Update Posted:
2007-11-01
First Post:
2003-04-01
Brief Title:
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkins Lymphoma Patients
Sponsor:
InterMune
Organization:
InterMune
Study Overview
Official Title:
Phase III Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low GradeFollicular Non-Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
administrative reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b IFN g-1b administered 3 times per week with Rituximab for 4 weeks in patients with progressive or relapsed low-grade Non-Hodgkins Lymphoma NHL
International study with sites in the Czech Republic and Poland
International study with sites in the Czech Republic and Poland
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None